CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...